regulus therapeutics inc
(RGLS:Consolidated Issue listed on NASDAQ Global Market)
Earnings & Estimates Summary - REGULUS THERAPEUTICS INC (RGLS)
2013 revenues at Regulus Therapeutics Inc. totaled $19.6M USD, while annual losses equaled $0.46 per share.
Quarterly Earnings & Estimates - REGULUS THERAPEUTICS INC (RGLS)
Regulus Therapeutics Inc.'s Quarterly Earnings
Regulus Therapeutics Inc. reported 2nd quarter 2014 losses of $0.28 per share on 08/8/2014.
Annual Earnings & Estimates - REGULUS THERAPEUTICS INC (RGLS)
Regulus Therapeutics Inc.'s Annual Earnings
Regulus Therapeutics Inc. reported annual 2013 losses of $0.46 per share on 03/1/2014.
Quarterly Revenues - REGULUS THERAPEUTICS INC (RGLS)
Regulus Therapeutics Inc.'s Quarterly Revenues
Regulus Therapeutics Inc. had 2nd quarter 2014 revenues of $736.0K USD. This missed the $3.2M USD consensus estimate of the 5 analysts following the company. This was -84.5% below the prior year's 2nd quarter results.
Annual Revenues - REGULUS THERAPEUTICS INC (RGLS)
Regulus Therapeutics Inc.'s Annual Revenues
Regulus Therapeutics Inc. had revenues for the full year 2013 of $19.6M USD. This was 54.1% above the prior year's results.
|Arbutus Biopharma Corp||$6.93 USD||0.00|
|Benitec Biopharma Ltd||A$0.51 AUD||-0.015|
|Dicerna Pharmaceuticals Inc||$10.63 USD||0.00|
|Galena Biopharma Inc||$1.62 USD||0.00|
|Silence Therapeutics PLC||255.00 GBp||-5.00|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|